



Clinical trial results:

A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS

Summary

EudraCT number	2009-012655-26
Trial protocol	GR
Global end of trial date	26 August 2014

Results information

Result version number	v1 (current)
This version publication date	14 November 2018
First version publication date	14 November 2018

Trial information

Trial identification

Sponsor protocol code	HE 6A/09
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01215539
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Hellenic Cooperative Oncology Group
Sponsor organisation address	Hatzikonstandi 18, Athens, Greece, 11524
Public contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr
Scientific contact	Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group, hecogoff@otenet.gr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 August 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 August 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To estimate the objective response rate in wild-type k-ras, metastatic colorectal cancer patients treated with panitumumab in combination with capecitabine/oxaliplatin as first-line therapy.

Protection of trial subjects:

This study was conducted in conformance with ICH GCP, all applicable laws and regulations. All participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 October 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Greece: 78
Worldwide total number of subjects	78
EEA total number of subjects	78

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	37
From 65 to 84 years	41
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled in the study from 13 October 2010 until 10 September 2013 from 12 sites in Greece.

Pre-assignment

Screening details:

All potentially eligible subjects underwent screening in order to confirm that all eligibility criteria were met prior to the first administration of the study treatment.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Panitumumab+capecitabine+oxaliplatin
-----------	--------------------------------------

Arm description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m² IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m² divided in two doses, orally, on Days 1 - 14.

Arm type	Experimental
Investigational medicinal product name	Panitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The starting panitumumab dose was 9 mg/kg iv administration on day 1 of each 3-week cycle.

Number of subjects in period 1	Panitumumab+capecitabine+oxaliplatin
Started	78
Completed	45
Not completed	33
Physician decision	5
Consent withdrawn by subject	6
Adverse event, non-fatal	3
Death	4
Other	3
Progression	10
Moved to other hospital	2

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	78	78	
Age categorical			
Units: Subjects			
Adults (18-64 years)	37	37	
From 65-84 years	41	41	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	63.4		
full range (min-max)	30.1 to 80.9	-	
Gender categorical			
Units: Subjects			
Female	33	33	
Male	45	45	

End points

End points reporting groups

Reporting group title	Panitumumab+capecitabine+oxaliplatin
-----------------------	--------------------------------------

Reporting group description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m² IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m² divided in two doses, orally, on Days 1 - 14.

Primary: Objective Response Rate

End point title	Objective Response Rate ^[1]
-----------------	--

End point description:

Response was centrally assessed using RECIST criteria. An objective response was defined as either a complete or a partial response.

End point type	Primary
----------------	---------

End point timeframe:

Tumor response was assessed every 6 weeks through week 18 and every 3 months thereafter, until disease progression

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The percentage of patients that achieved a complete or partial response out of the total number of enrolled patients is provided. No comparisons were performed since this was a single-arm study.

End point values	Panitumumab+capecitabine+oxaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: percentage of patients				
number (not applicable)	44.9			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival

End point title	Progression-Free Survival
-----------------	---------------------------

End point description:

Progression-free survival was defined as the time from the date of enrollment to the date of documented disease progression, death or last contact. Deaths without a documented progression were treated as events at the time of death for the PFS analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor response was assessed every 6 weeks through week 18 and every 3 months thereafter, until disease progression.

End point values	Panitumumab+ capecitabine+o xaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: months				
median (confidence interval 95%)	8.1 (6.5 to 9.9)			

Attachments (see zip file)	Kaplan-meier with respect to PFS/PFS_HE6A09.png
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Safety profile

End point title	Safety profile
-----------------	----------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Adverse Events of all participants were recorded and assessed upon signature of the Informed Consent Form, until 30 days after the last administration of study treatment.

End point values	Panitumumab+ capecitabine+o xaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: number of patients				
Any adverse event	76			
Adverse event grade≥3	54			
Adverse event grade≥4	12			
Fatal adverse events	6			
Serious adverse events	27			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival

End point title	Overall survival
-----------------	------------------

End point description:

Overall survival was defined as the time from enrollment to the date of death or last contact. Alive patients were censored at the date of their last contact.

End point type	Secondary
----------------	-----------

End point timeframe:

The median follow-up time was 12.8 months (range 0-39).

End point values	Panitumumab+ capecitabine+o xaliplatin			
Subject group type	Reporting group			
Number of subjects analysed	78			
Units: months				
median (confidence interval 95%)	23.2 (18.0 to 28.8)			

Attachments (see zip file)	Kaplan-meier curve with respect to OS/OS_HE6A09.png
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events of all participants were recorded and assessed upon signature of the Informed Consent Form, until 30 days after the last administration of study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.1
--------------------	------

Reporting groups

Reporting group title	Panitumumab+capecitabine+oxaliplatin
-----------------------	--------------------------------------

Reporting group description:

Panitumumab was administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose was 9 mg/kg. Oxaliplatin 130 mg/m² IV infusion over 2 hours on Day 1 of each cycle after the administration of panitumumab, capecitabine 2000 mg/m² divided in two doses, orally, on Days 1 - 14.

Serious adverse events	Panitumumab+capecitabine+oxaliplatin		
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 78 (34.62%)		
number of deaths (all causes)	26		
number of deaths resulting from adverse events	6		
Investigations			
Hyperbilirubinaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	1 / 1		
Phlebitis superficial			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Nervous system disorders			
Depressed level of consciousness	Additional description: Somnolence		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Neuropathy			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Neuropathy sensory			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

General disorders and administration site conditions			
Catheter site thrombosis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sudden death	Additional description: Cause unknown		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Immune system disorders			
Allergic reaction			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Vomiting			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Intestinal perforation			

subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Chronic obstructive pulmonary disease	Additional description: Exacerbation of Chronic Obstructive Pulmonary Disease		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	1 / 1		
Infections and infestations			
Infection			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Lung infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Infectious colitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Diverticulitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Panitumumab+cape citabine+oxaliplatin		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	76 / 78 (97.44%)		
Vascular disorders			
Phlebitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	26 / 78 (33.33%)		
occurrences (all)	36		
Insomnia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Fever			

subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Edema head and neck			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Edema limbs			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Flu like symptoms			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Pain			
subjects affected / exposed	10 / 78 (12.82%)		
occurrences (all)	11		
Immune system disorders			
Allergic reaction			
subjects affected / exposed	5 / 78 (6.41%)		
occurrences (all)	9		
Immune system disorder	Additional description: Allergy-Dermatology-Skin		
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Hemorrhage pulmonary			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Bronchospasm			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Dyspnoea			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	5		
Voice alteration			

subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Psychiatric disorders Confusional state subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Personality change subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Investigations Weight decreased subjects affected / exposed occurrences (all)	8 / 78 (10.26%) 8		
International normalised ratio increased subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	19 / 78 (24.36%) 33		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	36 / 78 (46.15%) 67		
Alkaline phosphatase increased subjects affected / exposed occurrences (all)	29 / 78 (37.18%) 38		
Amylase increased subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 3		
Blood bilirubin increased subjects affected / exposed occurrences (all)	20 / 78 (25.64%) 31		
Hypercholesterolaemia			

subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Creatinine increased			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Gamma-glutamyltransferase increased			
subjects affected / exposed	28 / 78 (35.90%)		
occurrences (all)	33		
Hyperkalaemia			
subjects affected / exposed	7 / 78 (8.97%)		
occurrences (all)	8		
Hypermagnesaemia			
subjects affected / exposed	9 / 78 (11.54%)		
occurrences (all)	11		
Hypernatraemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Hyperuricaemia			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Hypoalbuminaemia			
subjects affected / exposed	24 / 78 (30.77%)		
occurrences (all)	29		
Hypocalcaemia			
subjects affected / exposed	12 / 78 (15.38%)		
occurrences (all)	14		
Hypokalaemia			
subjects affected / exposed	22 / 78 (28.21%)		
occurrences (all)	37		
Hypomagnesaemia			
subjects affected / exposed	24 / 78 (30.77%)		
occurrences (all)	33		

Hyponatraemia subjects affected / exposed occurrences (all)	10 / 78 (12.82%) 15		
Hypophosphataemia subjects affected / exposed occurrences (all)	4 / 78 (5.13%) 6		
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	20 / 78 (25.64%) 35		
Blood urea increased subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		
Injury, poisoning and procedural complications Vascular access complication subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Cardiac disorders Hypotension subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Nervous system disorders Dysgeusia subjects affected / exposed occurrences (all)	5 / 78 (6.41%) 6		
Dizziness subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		
Mood altered subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		
Vertigo subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Peripheral motor neuropathy subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		

Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	35 / 78 (44.87%) 53		
Neuropathy cranial alternative dictionary used: CTCAE 3 subjects affected / exposed occurrences (all)	3 / 78 (3.85%) 4		
Speech disorder subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	28 / 78 (35.90%) 45		
Leukopenia subjects affected / exposed occurrences (all)	26 / 78 (33.33%) 46		
Neutropenia subjects affected / exposed occurrences (all)	24 / 78 (30.77%) 44		
Thrombocytopenia subjects affected / exposed occurrences (all)	26 / 78 (33.33%) 51		
Ear and labyrinth disorders			
Ear and labyrinth disorder- other	Additional description: Partial temporary hearing loss		
subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Eye disorders			
Dry eye subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Ocular surface disease subjects affected / exposed occurrences (all)	4 / 78 (5.13%) 4		
Gastrointestinal disorders			

Constipation			
subjects affected / exposed	11 / 78 (14.10%)		
occurrences (all)	13		
Diarrhoea			
subjects affected / exposed	34 / 78 (43.59%)		
occurrences (all)	60		
Flatulence			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Dry mouth			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Dysphagia			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Stomatitis			
subjects affected / exposed	10 / 78 (12.82%)		
occurrences (all)	13		
Nausea			
subjects affected / exposed	17 / 78 (21.79%)		
occurrences (all)	26		
Vomiting			
subjects affected / exposed	16 / 78 (20.51%)		
occurrences (all)	26		
Gastrointestinal pain			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Esophagitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Hemorrhage gastrointestinal			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		

Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	13 / 78 (16.67%)		
occurrences (all)	13		
Cheilitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Skin disorder			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Dry skin			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	20 / 78 (25.64%)		
occurrences (all)	23		
Nail disorder			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Photosensitivity reaction			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Rash			
subjects affected / exposed	56 / 78 (71.79%)		
occurrences (all)	63		
Hyperhidrosis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Hair growth rate abnormal			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Subcutaneous abscess			

subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		
Renal and urinary disorders Hematuria subjects affected / exposed occurrences (all) Hemorrhage GU alternative dictionary used: CTCAE 3 subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1 1 / 78 (1.28%) 1		
Infections and infestations Infections and infestations- Other specify subjects affected / exposed occurrences (all) Lower respiratory tract infection subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all) Viral infection subjects affected / exposed occurrences (all) Diverticulitis subjects affected / exposed occurrences (all) Nail infection subjects affected / exposed occurrences (all) Herpes virus infection subjects affected / exposed occurrences (all)	4 / 78 (5.13%) 5 1 / 78 (1.28%) 1 1 / 78 (1.28%) 1 1 / 78 (1.28%) 1 1 / 78 (1.28%) 1 1 / 78 (1.28%) 1 1 / 78 (1.28%) 1		
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	19 / 78 (24.36%) 24		

Hyperglycemia			
subjects affected / exposed	32 / 78 (41.03%)		
occurrences (all)	65		
Hypoglycaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported